IRadimed Corporation (IRMD)

Principal Financial Group Inc. bought a new position in iRadimed Corporation (NASDAQ: IRMD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,927 shares of the medical equipment provider's stock, valued at approximately $422,000. Several other hedge funds have also modified their

Nine Ten Capital Management sold 342,907 shares of IRadimed; the estimated transaction value was $29.42 million based on quarterly average price. The quarter-end position value decreased by $13.21 million, reflecting both share sales and price changes.

For the 18th time in a row, the niche medical device maker set a new all-time high for quarterly revenue. It also handily topped the consensus analyst estimate for adjusted net profit.

IRADIMED CORPORATION (IRMD) Q4 2025 Earnings Call Transcript

ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the quarter and year ended December 31, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) non-magnetic patient vital signs monitoring systems that are each designed for use during MRI procedures.

Shares of iRadimed Corporation (NASDAQ: IRMD - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price

iRadimed Corporation (NASDAQ: IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $97.66, for a total value of $488,300.00. Following the completion of the transaction, the chief executive officer owned 2,282,500 shares

Copeland Capital Management LLC lowered its position in shares of iRadimed Corporation (NASDAQ: IRMD) by 5.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 433,500 shares of the medical equipment provider's stock after selling 24,419 shares during the period.

ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company's outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company produces the only known non-magnetic intravenous (“IV”) infusion pump system and a non-magnetic patient vital signs monitoring system designed for use during MRI procedures.

STERIS (NYSE: STE - Get Free Report) and iRadimed (NASDAQ: IRMD - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a breakdown of recent ratings for

Thermo Fisher Scientific (NYSE: TMO - Get Free Report) and iRadimed (NASDAQ: IRMD - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of current

Shares of iRadimed Corporation (NASDAQ: IRMD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target

Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance

Iradimed's CEO, President, and Chairman of the Board, Roger Susi, recently sold 5,000 shares on the open market. The transaction represented roughly 1% of his indirect holdings.

Spire Wealth Management purchased a new position in shares of iRadimed Corporation (NASDAQ: IRMD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,000 shares of the medical equipment provider's stock, valued at approximately $60,000. Other institutional investors and hedge funds

AlphaQuest LLC lowered its position in shares of iRadimed Corporation (NASDAQ: IRMD) by 58.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,008 shares of the medical equipment provider's stock after selling 4,230 shares during the period. AlphaQuest LLC's holdings in iRadimed